2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2654

Treatment-Associated DNA Methylation Patterns in Systemic Lupus Erythematosus
Abstract Number: 2655

Contribution of Monocytes to Circulating microRNAs Related to Cardiovascular Disease in Systemic Lupus Erythematosus. Effects of In Vivo Treatment with Rituximab
Abstract Number: 2656

Alterations of the Splicing Machinery Components in Leukocytes from Systemic Lupus Erythematosus Patients Influences Its Development and Atherothrombotic Profile and Drives the Therapeutic Response
Abstract Number: 2657

Single Cell Expression Quantitative Trait Loci (eQTL) Analysis of Established Systemic Lupus Erythematosus (SLE)-Risk Loci in Lupus Patient Monocytes
Abstract Number: 2658

4-Hydroxy-2-Nonenal Serum Protein-Adducts and Anti-4-Hydroxy-2-Nonenal-Protein Adduct Antibodies in SLE
Abstract Number: 2659

Development of a Protocol for Single Cell Transcriptomics of Cells from Cryopreserved Lupus Nephritis Kidney Tissue and Urine for the Accelerating Medicines Partnership RA/SLE Network
Abstract Number: 2660

Endothelin-1 and Interleukin-6 Serum Levels Are Associated with More Severe Vasculopathy in Patients  with Systemic Sclerosis
Abstract Number: 2661

Clinical Impact of Selenium and Vitamin C Deficiency in Systemic Sclerosis
Abstract Number: 2662

The EULAR Systemic Sclerosis Impact of Disease (ScleroID) Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis – Preliminary Results from the Ongoing Validation Study
Abstract Number: 2663

Changes in Disability over Time, and Their Relationship with Degree of Skin Thickening, in Patients with Limited and Diffuse Cutaneous Systemic Sclerosis: A Retrospective Cohort Study
Abstract Number: 2664

Anti-SSA (Ro52/Ro60) and SSB Autoantibodies in Patients with Systemic Sclerosis
Abstract Number: 2665

Mortality in an Early Diffuse Cutaneous Systemic Sclerosis Cohort—Data from the Prospective Registry for Early Systemic Sclerosis
Abstract Number: 2666

The Clinical Utility of Flow-Mediated Dilation in Systemic Sclerosis Digital Ulcer Assessment
Abstract Number: 2667

The Association between Two Non-Invasive Methods for the Assessment of Severity of Gastrointestinal Involvement and Malnutrition in Systemic Sclerosis: Self-Reported Questionnaires and Nail Fold Video-Capillaroscopy
Abstract Number: 2668

Responsiveness of University of California Los Angeles Scleroderma Clinical Trial Consortium (GIT2.0) and Intestinal Visual Analogue Scale to Change in Systemic Sclerosis Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].